Janani Saravanan, K. V. Navyasree, Raiha Hareed, S. Swathi Krishna, Soumya Jagadeesan, Vidya Viswanad
{"title":"他克莫司和盐酸普拉莫辛皮肤递送微乳化凝胶","authors":"Janani Saravanan, K. V. Navyasree, Raiha Hareed, S. Swathi Krishna, Soumya Jagadeesan, Vidya Viswanad","doi":"10.1007/s12247-025-10066-9","DOIUrl":null,"url":null,"abstract":"<div>\n \n <span>AbstractSection</span>\n Purpose\n <p>Atopic dermatitis (AD) is a chronic, pruritic skin disorder usually treated with topical tacrolimus and corticosteroids, which are limited by adverse effects such as burning sensations and allergic reactions. We developed a new microemulgel formulation combining tacrolimus with pramoxine hydrochloride, an anesthetic that reduces pruritus by inhibiting voltage-gated sodium channels. This study aimed to optimize the formulation to augment skin retention and permeation of tacrolimus, potentially enhancing therapeutic efficacy and addressing current treatment limitations for AD.</p>\n \n <span>AbstractSection</span>\n Methods\n <p>The microemulgel formulation was optimized using a mixture design. The formulation was evaluated for physicochemical properties, in vitro drug release, ex vivo skin permeation and retention, cell viability (MTT assay), and efficacy in reducing inflammatory mediators (RT-PCR).</p>\n \n <span>AbstractSection</span>\n Results\n <p>The optimized formulation exhibited a favorable release profile, with a rapid initial release of pramoxine hydrochloride for immediate local anesthetic effects, followed by sustained release of tacrolimus for prolonged therapeutic action. Ex vivo permeation studies using porcine skin indicated enhanced permeation and increased drug retention compared to a marketed ointment. Cytotoxicity assays confirmed formulation safety, with cell viability above 90% at therapeutic concentrations. RT-PCR analysis showed a significant reduction in IL-1α expression. Stability studies at various temperatures demonstrated long-term stability and integrity, making the formulation suitable for practical use.</p>\n \n <span>AbstractSection</span>\n Conclusions\n <p>The successfully prepared microemulsion-based gel of tacrolimus and pramoxine hydrochloride demonstrated improved skin permeation and skin retention. This dual drug-loaded microemulgel offers a promising approach for AD treatment, providing immediate relief and sustained therapeutic effect, potentially improving patient complaints and treatment outcomes.</p>\n \n <span>AbstractSection</span>\n Graphical Abstract\n <div><figure><div><div><picture><source><img></source></picture></div></div></figure></div>\n \n </div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 5","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Microemulsion-Based Gel for Skin Delivery of Tacrolimus and Pramoxine Hydrochloride\",\"authors\":\"Janani Saravanan, K. V. Navyasree, Raiha Hareed, S. Swathi Krishna, Soumya Jagadeesan, Vidya Viswanad\",\"doi\":\"10.1007/s12247-025-10066-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <span>AbstractSection</span>\\n Purpose\\n <p>Atopic dermatitis (AD) is a chronic, pruritic skin disorder usually treated with topical tacrolimus and corticosteroids, which are limited by adverse effects such as burning sensations and allergic reactions. We developed a new microemulgel formulation combining tacrolimus with pramoxine hydrochloride, an anesthetic that reduces pruritus by inhibiting voltage-gated sodium channels. This study aimed to optimize the formulation to augment skin retention and permeation of tacrolimus, potentially enhancing therapeutic efficacy and addressing current treatment limitations for AD.</p>\\n \\n <span>AbstractSection</span>\\n Methods\\n <p>The microemulgel formulation was optimized using a mixture design. The formulation was evaluated for physicochemical properties, in vitro drug release, ex vivo skin permeation and retention, cell viability (MTT assay), and efficacy in reducing inflammatory mediators (RT-PCR).</p>\\n \\n <span>AbstractSection</span>\\n Results\\n <p>The optimized formulation exhibited a favorable release profile, with a rapid initial release of pramoxine hydrochloride for immediate local anesthetic effects, followed by sustained release of tacrolimus for prolonged therapeutic action. Ex vivo permeation studies using porcine skin indicated enhanced permeation and increased drug retention compared to a marketed ointment. Cytotoxicity assays confirmed formulation safety, with cell viability above 90% at therapeutic concentrations. RT-PCR analysis showed a significant reduction in IL-1α expression. Stability studies at various temperatures demonstrated long-term stability and integrity, making the formulation suitable for practical use.</p>\\n \\n <span>AbstractSection</span>\\n Conclusions\\n <p>The successfully prepared microemulsion-based gel of tacrolimus and pramoxine hydrochloride demonstrated improved skin permeation and skin retention. This dual drug-loaded microemulgel offers a promising approach for AD treatment, providing immediate relief and sustained therapeutic effect, potentially improving patient complaints and treatment outcomes.</p>\\n \\n <span>AbstractSection</span>\\n Graphical Abstract\\n <div><figure><div><div><picture><source><img></source></picture></div></div></figure></div>\\n \\n </div>\",\"PeriodicalId\":656,\"journal\":{\"name\":\"Journal of Pharmaceutical Innovation\",\"volume\":\"20 5\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Innovation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12247-025-10066-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10066-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Microemulsion-Based Gel for Skin Delivery of Tacrolimus and Pramoxine Hydrochloride
AbstractSection
Purpose
Atopic dermatitis (AD) is a chronic, pruritic skin disorder usually treated with topical tacrolimus and corticosteroids, which are limited by adverse effects such as burning sensations and allergic reactions. We developed a new microemulgel formulation combining tacrolimus with pramoxine hydrochloride, an anesthetic that reduces pruritus by inhibiting voltage-gated sodium channels. This study aimed to optimize the formulation to augment skin retention and permeation of tacrolimus, potentially enhancing therapeutic efficacy and addressing current treatment limitations for AD.
AbstractSection
Methods
The microemulgel formulation was optimized using a mixture design. The formulation was evaluated for physicochemical properties, in vitro drug release, ex vivo skin permeation and retention, cell viability (MTT assay), and efficacy in reducing inflammatory mediators (RT-PCR).
AbstractSection
Results
The optimized formulation exhibited a favorable release profile, with a rapid initial release of pramoxine hydrochloride for immediate local anesthetic effects, followed by sustained release of tacrolimus for prolonged therapeutic action. Ex vivo permeation studies using porcine skin indicated enhanced permeation and increased drug retention compared to a marketed ointment. Cytotoxicity assays confirmed formulation safety, with cell viability above 90% at therapeutic concentrations. RT-PCR analysis showed a significant reduction in IL-1α expression. Stability studies at various temperatures demonstrated long-term stability and integrity, making the formulation suitable for practical use.
AbstractSection
Conclusions
The successfully prepared microemulsion-based gel of tacrolimus and pramoxine hydrochloride demonstrated improved skin permeation and skin retention. This dual drug-loaded microemulgel offers a promising approach for AD treatment, providing immediate relief and sustained therapeutic effect, potentially improving patient complaints and treatment outcomes.
期刊介绍：
The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories:
Materials science,
Product design,
Process design, optimization, automation and control,
Facilities; Information management,
Regulatory policy and strategy,
Supply chain developments ,
Education and professional development,
Journal of Pharmaceutical Innovation publishes four issues a year.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
